3 results on '"Martino EA"'
Search Results
2. Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
- Author
-
Ernesto Vigna, Fortunato Morabito, Cirino Botta, Giovanni Martinelli, Francesco Mendicino, Enrica Antonia Martino, Concetta Conticello, Alessandra Romano, Massimo Gentile, Giuseppe Antonio Palumbo, Claudio Cerchione, Francesco Di Raimondo, Botta C, Martino EA, Conticello C, Mendicino F, Vigna E, Romano A, Palumbo GA, Cerchione C, Martinelli G, Morabito F, Di Raimondo F, and Gentile M
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Opinion ,lenalidomide ,lcsh:RC254-282 ,chemistry.chemical_compound ,Internal medicine ,medicine ,Lenalidomide ,Isatuximab ,carfilzomib ,Bortezomib ,business.industry ,network meta analysis ,bortezomib ,Daratumumab ,Refractory Multiple Myeloma ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,daratumumab ,Carfilzomib ,myeloma ,chemistry ,Meta-analysis ,business ,medicine.drug ,isatuximab - Abstract
Over the past 10 years, the treatment of multiple myeloma (MM) dramatically changed due to the introduction of a number of new agents and combination regimens both in the frontline and in the relapsed/refractory setting. Currently, at least 11 classes of therapeutic agents, including steroids, alkylators (melphalan and cyclophosphamide), proteasome inhibitors (PI: bortezomib, carfilzomib, ixazomib), immunomodulatory agents (thalidomide, lenalidomide, pomalidomide), monoclonal antibodies (mAbs: elotuzumab, daratumumab), HDAC-inhibitors (panobinostat), BCL2 inhibitors (venetoclax), selective inhibitors of nuclear export (selinexor), drug-conjugated mAbs (belantamab mafodotin), bispecific agents and CAR-T, are approved (or are going to be approved) alone or in different combinations for the treatment of this disease, while few or no data are available to guide the therapeutic strategy to adopt at diagnosis or relapse (1). The choice of the treatment at relapse (2), in particular, poses particular challenges, and is currently dependent on patients (age, comorbidities, fitness, renal impairment, frailty) and disease characteristics (aggressive vs biochemical relapse, cytogenetics, presence of extra-medullary disease), previous treatments (classes of agents, duration of response, progression while on therapy), regional drug access (approval of combinations, reimbursement, costs) and, finally, patient’s choice. Unfortunately, there is a lack of trials specifically designed to help in this choice, and often, pre-planned subgroup analyses, do not include a sufficient number of patients to reach statistical evidence. Recently, since lenalidomide is progressively becoming the preferred one-line option to treat MM patients (and often, it is administered until progression), the choice of the treatment to be offered at relapse should be carefully evaluated. Interestingly, it has been reported that the longest prior lenalidomide treatment duration (>12 months) and IMiD-free interval (>18 months) could positively impact patients’ outcome (3), making the choice of a lenalidomide-sparing regimen of particular interest in this setting. On the bases of these premises, we performed a systematic review and a frequentist network meta-analysis in R [by using the netmeta package (4)] comparing direct and indirect evidence on the efficacy of seven different lenalidomide-sparing regimens (bortezomib-dexamethasone, VD; daratumumab-VD, DVD; carfilzomib-D, KD; daratumumab-KD, KdD; pomalidomide-VD, PVD; isatuximab-KD, IKD; selinexor-VD, SVD) in lenalidomide-exposed and lenalidomide-refractory patients, to provide statistical evidence to support clinical decision making
- Published
- 2020
3. Silent cerebral injury after transcatheter aortic valve implantation and the preventive role of embolic protection devices: A systematic review and meta-analysis
- Author
-
Matteo Pagnesi, Enrico Antonio Martino, Mauro Chiarito, Richard J. Jabbour, Antonio Colombo, Nicolas M. Van Mieghem, Antonio Mangieri, Cosmo Godino, Azeem Latib, Giovanni Landoni, Susheel Kodali, Cardiology, Pagnesi, M, Martino, Ea, Chiarito, M, Mangieri, A, Jabbour, Rj, Van Mieghem, Nm, Kodali, Sk, Godino, C, Landoni, Giovanni, Colombo, A, and Latib, A.
- Subjects
medicine.medical_specialty ,030204 cardiovascular system & hematology ,Embolic Protection Devices ,Transcatheter Aortic Valve Replacement ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,medicine ,Humans ,030212 general & internal medicine ,Prospective cohort study ,Stroke ,Cerebral injury ,medicine.diagnostic_test ,business.industry ,Magnetic resonance imaging ,Aortic Valve Stenosis ,medicine.disease ,Confidence interval ,Diffusion Magnetic Resonance Imaging ,Treatment Outcome ,Aortic valve stenosis ,Meta-analysis ,Asymptomatic Diseases ,Radiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
Background The aims of this study were: 1) to evaluate silent cerebral injury detected by cerebral diffusion weighted magnetic resonance imaging (DW-MRI) after transcatheter aortic valve implantation (TAVI); and 2) to assess the efficacy of embolic protection devices (EPDs) on DW-MRI endpoints. Methods We included in a pooled analysis 25 prospective studies reporting post-procedural cerebral DW-MRI data after TAVI (n=1225). Among these studies, we included in a meta-analysis 6 studies investigating TAVI performed with versus without EPDs (n=384). Primary endpoints were the number of new lesions per patient and the total lesion volume, while secondary endpoints were the number of patients with new lesions and the single lesion volume. Results The main pooled DW-MRI outcomes were: patients with new ischemic lesions, 77.5% (95% confidence interval=71.7–83.3%); total lesion volume, 437.5mm 3 (286.7–588.3mm 3 ); single lesion volume, 78.1mm 3 (56.7–99.5mm 3 ); and number of new lesions per patient, 4.2 (3.4–5.0). The use of EPDs was associated with a significant reduction in total lesion volume (mean difference [95% confidence interval]=−111.1mm 3 [−203.6 to −18.6mm 3 ]; p=0.02) and single lesion volume (−12.1mm 3 [−18.3 to −6.0mm 3 ]; p=0.0001) after TAVI. Conclusions Silent cerebral injury occurs in the majority of patients undergoing TAVI and DW-MRI allows a precise characterization of new ischemic brain lesions. EPDs reduce the total and single volume of such lesions detected after the procedure, although the number of new lesions per patient and the number of patients with new lesions are not significantly reduced by such devices.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.